en
/
sv
About Elicera
Elicera in brief
Board
Management
Elicera's history
Immuno-oncology
What is immuno-oncology?
Oncolytic virus
CAR T-cell therapy
Technology
Strengths
ELC-001
ELC-100
ELC-201
ELC-301
ELC-401
Patents
Pipeline
Pipeline
Clinical trials
News
News
Press Releases
Investors
Press Releases
Articles of Association
General Meeting
Board
Management
the Share
Financial Reports
Financial Calendar
Contact
Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses
October 5, 2020
Read the press release in Swedish:
Download press release (pdf)
< Back to press releases
